BR0307091A - Método para produzir um composto, composto, uso do mesmo, composição farmacêutica, e, método para tratar uma doença ou condição que resulte de ativação inapropriada do músculo liso - Google Patents

Método para produzir um composto, composto, uso do mesmo, composição farmacêutica, e, método para tratar uma doença ou condição que resulte de ativação inapropriada do músculo liso

Info

Publication number
BR0307091A
BR0307091A BR0307091-3A BR0307091A BR0307091A BR 0307091 A BR0307091 A BR 0307091A BR 0307091 A BR0307091 A BR 0307091A BR 0307091 A BR0307091 A BR 0307091A
Authority
BR
Brazil
Prior art keywords
compound
disease
treating
pharmaceutical composition
producing
Prior art date
Application number
BR0307091-3A
Other languages
English (en)
Inventor
Andrew Jones
Jonathan Moseley
Ian Patel
Evan Snape
Maureen Young
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR0307091A publication Critical patent/BR0307091A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

"MéTODO PARA PRODUZIR UM COMPOSTO, COMPOSTO, USO DO MESMO, COMPOSIçãO FARMACêUTICA, E, MéTODO PARA TRATAR UMA DOENçA OU CONDIçãO QUE RESULTE DE ATIVAçãO INAPROPRIADA DO MúSCULO LISO". Um novo processo para preparar 3-[(4S)-5-oxo-2-(trifluorometil)- 1,4,5,6,7,8-hexaidroquinolin-4-il]benzonitrila, composições farmacêuticas contendo o composto e métodos de tratamento empregando-as.
BR0307091-3A 2002-01-24 2003-01-23 Método para produzir um composto, composto, uso do mesmo, composição farmacêutica, e, método para tratar uma doença ou condição que resulte de ativação inapropriada do músculo liso BR0307091A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0200205A SE0200205D0 (sv) 2002-01-24 2002-01-24 Method
PCT/SE2003/000114 WO2003062203A1 (en) 2002-01-24 2003-01-23 Method

Publications (1)

Publication Number Publication Date
BR0307091A true BR0307091A (pt) 2004-12-28

Family

ID=20286758

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0307091-3A BR0307091A (pt) 2002-01-24 2003-01-23 Método para produzir um composto, composto, uso do mesmo, composição farmacêutica, e, método para tratar uma doença ou condição que resulte de ativação inapropriada do músculo liso

Country Status (12)

Country Link
US (1) US7012145B2 (pt)
EP (1) EP1478627A1 (pt)
JP (1) JP2005520813A (pt)
KR (1) KR20040077782A (pt)
CN (1) CN1622938A (pt)
BR (1) BR0307091A (pt)
CA (1) CA2473386A1 (pt)
MX (1) MXPA04007055A (pt)
NO (1) NO20043433L (pt)
SE (1) SE0200205D0 (pt)
WO (1) WO2003062203A1 (pt)
ZA (1) ZA200405860B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006065842A2 (en) * 2004-12-13 2006-06-22 Synta Pharmaceuticals Corp. 5,6,7,8-tetrahydroquinolines and related compounds and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5455253A (en) * 1992-10-20 1995-10-03 Zeneca Limited Heterocyclic derivatives
GB9407432D0 (en) 1994-04-14 1994-06-08 Zeneca Ltd Heterocyclic derivative
AU2001282744A1 (en) * 2000-08-02 2002-02-13 Astrazeneca Ab Process for asymmetric synthesis of substituted 1,4-dihydropyridines

Also Published As

Publication number Publication date
US20050080104A1 (en) 2005-04-14
MXPA04007055A (es) 2004-10-11
US7012145B2 (en) 2006-03-14
KR20040077782A (ko) 2004-09-06
CA2473386A1 (en) 2003-07-31
WO2003062203A1 (en) 2003-07-31
ZA200405860B (en) 2005-08-15
CN1622938A (zh) 2005-06-01
NO20043433L (no) 2004-08-17
SE0200205D0 (sv) 2002-01-24
EP1478627A1 (en) 2004-11-24
JP2005520813A (ja) 2005-07-14

Similar Documents

Publication Publication Date Title
BRPI0307351B8 (pt) composto, composição farmacêutica, uso de um composto, e, processo para preparar um composto
BR0212733A (pt) Composto, composição farmacêutica, uso de um composto, e, método para o tratamento de um distúrbio afetivo
BR0209468A (pt) Composto ou sais ou solvatos deste farmaceuticamente aceitáveis, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada pelo hppar
BR0111898A (pt) Métodos de tratamento de doenças de proliferação celular, e de um distúrbio associado com a atividade de cinesina ksp, método de inibição da cinesina ksp, composto, método de triagem de moduladores da cinesina kps, e, método de triagem de compostos que se ligam à cinesina ksp
BR0116370A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
BR0309546A (pt) Composto, composição farmacêutica que compreende o mesmo, processo para a sua preparação e utilização e método para tratamento profilático ou terapêutico de diabetes do tipo ii
BR0014767A (pt) Fibras de sementes de plantas e uso
BG108225A (en) Thiohydantoins and use thereof for treating diabetes
BR0309278A (pt) Composto, composição, métodos para modular a atividade da cinesina ksp, para inibir a ksp, para o tratamento de uma doença proliferativa celular, e, uso de um composto
BRPI0411743A (pt) método e composições para tratar doenças relacionadas a amilóides
BRPI0408681A (pt) compostos, composições farmacêuticas, uso de um derivado da 1,2,3,4-tetraidroisoquinolina, método para tratar ou prevenir doenças, processo para a manufatura de composições farmacêuticas, e, uso de um ou mais compostos
BR0111116A (pt) Imitadores de trombopoietina
BR0108600A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, métodos para tratamento de uma doença mediada por quimiocina e para tratamento de uma doença inflamatória
BR0313234A (pt) Composto, uso do mesmo, método de tratamento ou profilaxia de doenças, composição farmacêutica, e, processo para a preparação de um composto
BRPI0412971A (pt) método de alongamento do cabelo
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
BR0211739A (pt) Novas formas polimórficas cristalinas de cloridrato de lercanidipina e processo para preparação das mesmas
AU2002321232A1 (en) Treatment of hair follicle with neurokinin 1 receptor antagonists
BRPI0417360A (pt) método para a preparação de multiparticulados farmacêuticos
BR0308957A (pt) Composto, composição farmacêutica, método para o tratamento de uma inflamação ou de uma desordem associada a uma inflamação em um paciente, uso dos compostos e processo para sua preparação
HUP0402173A2 (hu) Eljárások izomtömeg vagy -funkció szabályozására szolgáló vegyületek azonosítására
ATE369348T1 (de) Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie
BR0309406A (pt) Composição farmacêutica, processo de preparação, kit e métodos para tratamento de obesidade, utilização de composição e inibidor de lìpases, inibidor de lìpáses e glucomanan ou konjac e utilização dos mesmos e método de tratamento
PL350568A1 (en) N-(2-phenyl-4-aminobutyl)-1-naphtamides as antagonists of neurokinin 1 receptors
WO2004026258A3 (en) Modulating vesicular monoamine transporter trafficking and function: a novel approach for the treatment of parkinson’s disease

Legal Events

Date Code Title Description
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]